市場調查報告書

特發性肺纖維化(IPF) - 市場洞察,流行病學,市場預測 2028年

Idiopathic Pulmonary Fibrosis - Market Insight, Epidemiology and Market Forecast - 2030

出版商 DelveInsight Business Research LLP 商品編碼 650525
出版日期 內容資訊 英文 150 Pages
商品交期: 最快1-2個工作天內
價格
特發性肺纖維化(IPF) - 市場洞察,流行病學,市場預測 2028年 Idiopathic Pulmonary Fibrosis - Market Insight, Epidemiology and Market Forecast - 2030
出版日期: 2020年01月01日內容資訊: 英文 150 Pages
簡介

主要8個國家(美國、加拿大、英國、德國、法國、義大利、西班牙、日本)的突發性肺纖維症(IPF)的患病數2017年為22萬9,170人,以及市場規模估計為16億4,440萬美元。

本報告提供主要8個國家(美國、加拿大、英國、德國、法國、義大利、西班牙、日本)的突發性肺纖維症(IPF)市場調查,疾病概要和現行的治療方法,已上市治療藥,新藥及候補藥的簡介,整體及各國的市場趨勢,流行病學的預測,市場規模,患病數的變化與預測,未滿足需求,市場成長要素及障礙等資訊總括性彙整。

目錄

第1章 主要洞察

第2章 突發性肺纖維症(IPF)概要

  • 市場佔有率(成果值)
  • 市場佔有率(預測值)

第3章 疾病背景和概要

  • 簡介
  • 突發性肺纖維化(IPF)的病期分類
  • 危險因素
  • 症狀
  • 病因
  • 診斷

第4章 流行病學和患者人口

  • 主要調查結果
  • 主要8個國家的診斷數
  • 各國流行病學
    • 美國
    • 加拿大
    • 歐盟5國
      • 法國
      • 德國
      • 義大利
      • 西班牙
      • 英國
    • 日本

第5章 現行的治療方法

  • ATS/ERS/JRS/ALAT診療指南:突發性肺纖維化的治療

第6章 未滿足需求

第7章 已上市產品

  • Esbriet (Pirfenidone): InterMune Inc.
    • 產品概要
    • 法規的里程碑
    • 優點與缺點
    • 安全性和有效性
    • 副作用
    • 產品簡介
  • Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co.
    • 安全性和有效性
    • 副作用

第8章 新藥

  • 關鍵交叉競爭
  • Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
    • 產品概要
    • 產品簡介
    • 臨床開發
    • 臨床試驗資訊
    • 安全性和有效性
  • GLPG1690:Galapagos NV
    • 法規的里程碑
    • 其他開發活動

第9章 有潛力候補藥

  • CC-90001:Celgene Corporation
    • 產品概要
    • 產品簡介
    • 臨床開發
    • 安全性和有效性
  • LT-1001:LTT Bio-Pharma
    • 法規的里程碑
    • 其他開發活動
  • BG00011:Biogen Inc
    • 臨床試驗資訊

第10章 突發性肺纖維化(IPF)市場分析

  • 主要調查結果
  • 主要8個國家的整體市場規模
  • 主要8個國家的市場規模:各治療藥物
  • 各國市場規模
    • 美國
    • 加拿大
    • 歐盟5國
      • 德國
      • 法國
      • 義大利
      • 英國
      • 西班牙
    • 日本

第11章 市場成長要素

第12章 市場障礙

第13章 附錄

  • 調查手法

第14章 DelveInsight的服務內容

第15章 免責聲明

第16章 關於DelveInsight

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DIMI0111

DelveInsight's "Idiopathic Pulmonary Fibrosis - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Idiopathic Pulmonary Fibrosis, historical and forecasted epidemiology as well as the Idiopathic Pulmonary Fibrosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Idiopathic Pulmonary Fibrosis market report provides current treatment practices, emerging drugs, Idiopathic Pulmonary Fibrosis market share of the individual therapies, current and forecasted Idiopathic Pulmonary Fibrosis market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Idiopathic Pulmonary Fibrosis treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Idiopathic Pulmonary Fibrosis Disease Understanding and Treatment Algorithm

The DelveInsight Idiopathic Pulmonary Fibrosis market report gives a thorough understanding of the Idiopathic Pulmonary Fibrosis by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Idiopathic Pulmonary Fibrosis.

Treatment

It covers the details of conventional and current medical therapies available in the Idiopathic Pulmonary Fibrosis market for the treatment of the condition. It also provides Idiopathic Pulmonary Fibrosis treatment algorithms and guidelines in the United States, Europe, and Japan.

Idiopathic Pulmonary Fibrosis Epidemiology

The Idiopathic Pulmonary Fibrosis epidemiology division provide insights about historical and current Idiopathic Pulmonary Fibrosis patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Idiopathic Pulmonary Fibrosis epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- Idiopathic Pulmonary Fibrosis Epidemiology

The epidemiology segment also provides the Idiopathic Pulmonary Fibrosis epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Idiopathic Pulmonary Fibrosis Drug Chapters

Drug chapter segment of the Idiopathic Pulmonary Fibrosis report encloses the detailed analysis of Idiopathic Pulmonary Fibrosis marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Idiopathic Pulmonary Fibrosis clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

The report provides the details of the marketed product available for Idiopathic Pulmonary Fibrosis treatment.

Idiopathic Pulmonary Fibrosis Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Idiopathic Pulmonary Fibrosis treatment.

Idiopathic Pulmonary Fibrosis Market Outlook

The Idiopathic Pulmonary Fibrosis market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Idiopathic Pulmonary Fibrosis market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Idiopathic Pulmonary Fibrosis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Idiopathic Pulmonary Fibrosis market in 7MM is expected to change in the study period 2017-2030.

Key Findings

This section includes a glimpse of the Idiopathic Pulmonary Fibrosis market in 7MM.

The United States Market Outlook

This section provides the total Idiopathic Pulmonary Fibrosis market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Idiopathic Pulmonary Fibrosis market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Idiopathic Pulmonary Fibrosis market size and market size by therapies in Japan is also mentioned.

Idiopathic Pulmonary Fibrosis Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Idiopathic Pulmonary Fibrosis market or expected to get launched in the market during the study period 2017-2030. The analysis covers Idiopathic Pulmonary Fibrosis market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Idiopathic Pulmonary Fibrosis Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Idiopathic Pulmonary Fibrosis key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Idiopathic Pulmonary Fibrosis emerging therapies.

Reimbursement Scenario in Idiopathic Pulmonary Fibrosis

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Idiopathic Pulmonary Fibrosis domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Idiopathic Pulmonary Fibrosis market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Idiopathic Pulmonary Fibrosis Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Idiopathic Pulmonary Fibrosis, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Idiopathic Pulmonary Fibrosis epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Idiopathic Pulmonary Fibrosis are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Idiopathic Pulmonary Fibrosis market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Idiopathic Pulmonary Fibrosis market

Report Highlights

  • In the coming years, Idiopathic Pulmonary Fibrosis market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Idiopathic Pulmonary Fibrosis R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Idiopathic Pulmonary Fibrosis. Launch of emerging therapies will significantly impact the Idiopathic Pulmonary Fibrosis market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Idiopathic Pulmonary Fibrosis
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Idiopathic Pulmonary Fibrosis Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Idiopathic Pulmonary Fibrosis Pipeline Analysis
  • Idiopathic Pulmonary Fibrosis Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Idiopathic Pulmonary Fibrosis Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage

Idiopathic Pulmonary Fibrosis Epidemiology Segmentation

  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Idiopathic Pulmonary Fibrosis Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Idiopathic Pulmonary Fibrosis market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Idiopathic Pulmonary Fibrosis total market size as well as market size by therapies across the 7MM during the forecast period (2017-2030)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Idiopathic Pulmonary Fibrosis market size during the forecast period (2017-2030)?
  • At what CAGR, the Idiopathic Pulmonary Fibrosis market is expected to grow in 7MM during the forecast period (2017-2030)?
  • What would be the Idiopathic Pulmonary Fibrosis market outlook across the 7MM during the forecast period (2017-2030)?
  • What would be the Idiopathic Pulmonary Fibrosis market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of the Idiopathic Pulmonary Fibrosis?
  • What is the historical Idiopathic Pulmonary Fibrosis patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Idiopathic Pulmonary Fibrosis in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Idiopathic Pulmonary Fibrosis?
  • Out of all 7MM countries, which country would have the highest prevalent population of Idiopathic Pulmonary Fibrosis during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?
  • Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
  • What are the current options for the Idiopathic Pulmonary Fibrosis treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Idiopathic Pulmonary Fibrosis in the USA, Europe, and Japan?
  • What are the Idiopathic Pulmonary Fibrosis marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Idiopathic Pulmonary Fibrosis?
  • How many therapies are developed by each company for Idiopathic Pulmonary Fibrosis treatment?
  • How many are emerging therapies in mid-stage, and late stage of development for Idiopathic Pulmonary Fibrosis treatment?
  • What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Idiopathic Pulmonary Fibrosis therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Idiopathic Pulmonary Fibrosis and their status?
  • What are the key designations that have been granted for the emerging therapies for Idiopathic Pulmonary Fibrosis?
  • What are the global historical and forecasted market of Idiopathic Pulmonary Fibrosis?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Idiopathic Pulmonary Fibrosis market
  • To understand the future market competition in the Idiopathic Pulmonary Fibrosis market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Idiopathic Pulmonary Fibrosis in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Idiopathic Pulmonary Fibrosis market
  • To understand the future market competition in the Idiopathic Pulmonary Fibrosis market

Table of Contents

1. Key Insights

2. Executive Summary of Idiopathic Pulmonary Fibrosis

3. Competitive Intelligence Analysis for Idiopathic Pulmonary Fibrosis

4. Idiopathic Pulmonary Fibrosis: Market Overview at a Glance

  • 4.1. Idiopathic Pulmonary Fibrosis Total Market Share (%) Distribution in 2017
  • 4.2. Idiopathic Pulmonary Fibrosis Total Market Share (%) Distribution in 2030

5. Idiopathic Pulmonary Fibrosis: Disease Background and Overview

  • 5.1. Introduction
  • 5.2. Sign and Symptoms
  • 5.3. Pathophysiology
  • 5.4. Risk Factors
  • 5.5. Diagnosis

6. Patient Journey

7. Idiopathic Pulmonary Fibrosis Epidemiology and Patient Population

  • 7.1. Epidemiology Key Findings
  • 7.2. Assumptions and Rationale: 7MM
  • 7.3. Epidemiology Scenario: 7MM
    • 7.3.1. Idiopathic Pulmonary Fibrosis Epidemiology Scenario in the 7MM (2017-2030)
  • 7.4. United States Epidemiology
    • 7.4.1. Idiopathic Pulmonary Fibrosis Epidemiology Scenario in the United States (2017-2030)
  • 7.5. EU-5 Country-wise Epidemiology
    • 7.5.1. Germany Epidemiology
      • 7.5.1.1. Idiopathic Pulmonary Fibrosis Epidemiology Scenario in Germany (2017-2030)
    • 7.5.2. France Epidemiology
      • 7.5.2.1. Idiopathic Pulmonary Fibrosis Epidemiology Scenario in France (2017-2030)
    • 7.5.3. Italy Epidemiology
      • 7.5.3.1. Idiopathic Pulmonary Fibrosis Epidemiology Scenario in Italy (2017-2030)
    • 7.5.4. Spain Epidemiology
      • 7.5.4.1. Idiopathic Pulmonary Fibrosis Epidemiology Scenario in Spain (2017-2030)
    • 7.5.5. United Kingdom Epidemiology
      • 7.5.5.1. Idiopathic Pulmonary Fibrosis Epidemiology Scenario in the United Kingdom (2017-2030)
    • 7.5.6. Japan Epidemiology
      • 7.5.6.1. Idiopathic Pulmonary Fibrosis Epidemiology Scenario in Japan (2017-2030)

8. Treatment Algorithm, Current Treatment, and Medical Practices

  • 8.1. Idiopathic Pulmonary Fibrosis Treatment and Management
  • 8.2. Idiopathic Pulmonary Fibrosis Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Idiopathic Pulmonary Fibrosis Treatment

11. Marketed Products

  • 11.1. List of Marketed Products in the 7MM
  • 11.2. Drug Name: Company Name
    • 11.2.1. Product Description
    • 11.2.2. Regulatory Milestones
    • 11.2.3. Other Developmental Activities
    • 11.2.4. Pivotal Clinical Trials
    • 11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

  • 12.1. Key Cross
  • 12.2. Drug Name: Company Name
    • 12.2.1. Product Description
    • 12.2.2. Other Developmental Activities
    • 12.2.3. Clinical Development
    • 12.2.4. Safety and Efficacy
    • 12.2.5. Product Profile

List to be continued in report

13. Idiopathic Pulmonary Fibrosis: Seven Major Market Analysis

  • 13.1. Key Findings
  • 13.2. Idiopathic Pulmonary Fibrosis Market Size in 7MM
  • 13.3. Idiopathic Pulmonary Fibrosis Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

  • 15.1. United States: Market Size
    • 15.1.1. Idiopathic Pulmonary Fibrosis Total Market Size in the United States
    • 15.1.2. Idiopathic Pulmonary Fibrosis Market Size by Therapies in the United States
  • 15.2. EU-5 countries: Market Size and Outlook
  • 15.3. Germany Market Size
    • 15.3.1. Idiopathic Pulmonary Fibrosis Total Market Size in Germany
    • 15.3.2. Idiopathic Pulmonary Fibrosis Market Size by Therapies in Germany
  • 15.4. France Market Size
    • 15.4.1. Idiopathic Pulmonary Fibrosis Total Market Size in France
    • 15.4.2. Idiopathic Pulmonary Fibrosis Market Size by Therapies in France
  • 15.5. Italy Market Size
    • 15.5.1. Idiopathic Pulmonary Fibrosis Total Market Size in Italy
    • 15.5.2. Idiopathic Pulmonary Fibrosis Market Size by Therapies in Italy
  • 15.6. Spain Market Size
    • 15.6.1. Idiopathic Pulmonary Fibrosis Total Market Size in Spain
    • 15.6.2. Idiopathic Pulmonary Fibrosis Market Size by Therapies in Spain
  • 15.7. United Kingdom Market Size
    • 15.7.1. Idiopathic Pulmonary Fibrosis Total Market Size in the United Kingdom
    • 15.7.2. Idiopathic Pulmonary Fibrosis Market Size by Therapies in the United Kingdom
  • 15.8. Japan Market Outlook
    • 15.8.1. Japan Market Size
    • 15.8.2. Idiopathic Pulmonary Fibrosis Total Market Size in Japan
    • 15.8.3. Idiopathic Pulmonary Fibrosis Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Idiopathic Pulmonary Fibrosis

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

  • 20.1. Bibliography
  • 20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

List of Tables

  • Table 1 : 7MM Idiopathic Pulmonary Fibrosis Epidemiology (2017-2030)
  • Table 2 : 7MM Idiopathic Pulmonary Fibrosis Diagnosed and Treatable Cases (2017-2030)
  • Table 3 : Disease% Epidemiology in the United States (2017-2030)
  • Table 4 : Idiopathic Pulmonary Fibrosis Diagnosed and Treatable Cases in the United States (2017-2030)
  • Table 5 : Idiopathic Pulmonary Fibrosis Epidemiology in Germany (2017-2030)
  • Table 6 : Idiopathic Pulmonary Fibrosis Diagnosed and Treatable Cases in Germany (2017-2030)
  • Table 7 : Idiopathic Pulmonary Fibrosis Epidemiology in France (2017-2030)
  • Table 8 : Idiopathic Pulmonary Fibrosis Diagnosed and Treatable Cases in France (2017-2030)
  • Table 9 : Idiopathic Pulmonary Fibrosis Epidemiology in Italy (2017-2030)
  • Table 10 : Idiopathic Pulmonary Fibrosis Diagnosed and Treatable Cases in Italy (2017-2030)
  • Table 11 : Idiopathic Pulmonary Fibrosis Epidemiology in Spain (2017-2030)
  • Table 12 : Idiopathic Pulmonary Fibrosis Diagnosed and Treatable Cases in Spain (2017-2030)
  • Table 13 : Idiopathic Pulmonary Fibrosis Epidemiology in the UK (2017-2030)
  • Table 14 : Idiopathic Pulmonary Fibrosis Diagnosed and Treatable Cases in the UK (2017-2030)
  • Table 15 : Idiopathic Pulmonary Fibrosis Epidemiology in Japan (2017-2030)
  • Table 16 : Idiopathic Pulmonary Fibrosis Diagnosed and Treatable Cases in Japan (2017-2030)
  • Table 17 : Drug Name, Clinical Trials by Recruitment status
  • Table 18 : Drug Name, Clinical Trials by Zone
  • Table 19 : Total Seven Major Market Size in USD, Million (2017-2030)
  • Table 20 : Region-wise Market Size in USD, Million (2017-2030)
  • Table 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)
  • Table 22 : United States Market Size in USD, Million (2017-2030)
  • Table 23 : United States Market Size by Therapy in USD, Million (2017-2030)
  • Table 24 : Germany Market Size in USD, Million (2017-2030)
  • Table 25 : Germany Market Size by Therapy in USD, Million (2017-2030)
  • Table 26 : France Market Size in USD, Million (2017-2030)
  • Table 27 : France Market Size by Therapy in USD, Million (2017-2030)
  • Table 28 : Italy Market Size in USD, Million (2017-2030)
  • Table 29 : Italy Market Size by Therapy in USD, Million (2017-2030)
  • Table 30 : Spain Market Size in USD, Million (2017-2030)
  • Table 31 : Spain Market Size by Therapy in USD, Million (2017-2030)
  • Table 32 : United Kingdom Market Size in USD, Million (2017-2030)
  • Table 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)
  • Table 34 : Japan Market Size in USD, Million (2017-2030)
  • Table 35 : Japan Market Size by Therapy in USD, Million (2017-2030)

List of Figures

  • Figure 1 : 7MM Idiopathic Pulmonary Fibrosis Epidemiology (2017-2030)
  • Figure 2 : 7MM Idiopathic Pulmonary Fibrosis Diagnosed and Treatable Cases (2017-2030)
  • Figure 3 : Idiopathic Pulmonary Fibrosis Epidemiology in the United States (2017-2030)
  • Figure 4 : Idiopathic Pulmonary Fibrosis Diagnosed and Treatable Cases in the United States (2017-2030)
  • Figure 5 : Idiopathic Pulmonary Fibrosis Epidemiology in Germany (2017-2030)
  • Figure 6 : Idiopathic Pulmonary Fibrosis Diagnosed and Treatable Cases in Germany (2017-2030)
  • Figure 7 : Idiopathic Pulmonary Fibrosis Epidemiology in France (2017-2030)
  • Figure 8 : Idiopathic Pulmonary Fibrosis Diagnosed and Treatable Cases in France (2017-2030)
  • Figure 9 : Idiopathic Pulmonary Fibrosis Epidemiology in Italy (2017-2030)
  • Figure 10 : Idiopathic Pulmonary Fibrosis Diagnosed and Treatable Cases in Italy (2017-2030)
  • Figure 11 : Idiopathic Pulmonary Fibrosis Epidemiology in Spain (2017-2030)
  • Figure 12 : Idiopathic Pulmonary Fibrosis Diagnosed and Treatable Cases in Spain (2017-2030)
  • Figure 13 : Idiopathic Pulmonary Fibrosis Epidemiology in the UK (2017-2030)
  • Figure 14 : Idiopathic Pulmonary Fibrosis Diagnosed and Treatable Cases in the UK (2017-2030)
  • Figure 15 : Idiopathic Pulmonary Fibrosis Epidemiology in Japan (2017-2030)
  • Figure 16 : Idiopathic Pulmonary Fibrosis Diagnosed and Treatable Cases in Japan (2017-2030)
  • Figure 17 : Drug Name, Clinical Trials by Recruitment status
  • Figure 18 : Drug Name, Clinical Trials by Zone
  • Figure 19 : Total Seven Major Market Size in USD, Million (2017-2030)
  • Figure 20 : Region-wise Market Size in USD, Million (2017-2030)
  • Figure 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)
  • Figure 22 : United States Market Size in USD, Million (2017-2030)
  • Figure 23 : United States Market Size by Therapy in USD, Million (2017-2030)
  • Figure 24 : Germany Market Size in USD, Million (2017-2030)
  • Figure 25 : Germany Market Size by Therapy in USD, Million (2017-2030)
  • Figure 26 : France Market Size in USD, Million (2017-2030)
  • Figure 27 : France Market Size by Therapy in USD, Million (2017-2030)
  • Figure 28 : Italy Market Size in USD, Million (2017-2030)
  • Figure 29 : Italy Market Size by Therapy in USD, Million (2017-2030)
  • Figure 30 : Spain Market Size in USD, Million (2017-2030)
  • Figure 31 : Spain Market Size by Therapy in USD, Million (2017-2030)
  • Figure 32 : United Kingdom Market Size in USD, Million (2017-2030)
  • Figure 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)
  • Figure 34 : Japan Market Size in USD, Million (2017-2030)
  • Figure 35 : Japan Market Size by Therapy in USD, Million (2017-2030)